<https://investingnews.com/news/pharmaceutical-investing/fda-approves-mercks-keytruda-for-patients-with-recurrent-or-metastatic-cutaneous-squamous-cell-carcinoma/#webpage>
<http://schema.org/description>
"Merck announced today that the US Food and Drug Administration has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation."
<https://investingnews.com/news/pharmaceutical-investing/fda-approves-mercks-keytruda-for-patients-with-recurrent-or-metastatic-cutaneous-squamous-cell-carcinoma/>